LP
TARA icon

Longaeva Partners’s Protara Therapeutics TARA Stock Holding History

Longaeva Partners’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,857
Closed -$180K – 243
2025
Q4 		$180K Buy
+33,857
New +$188K 0.02% 117

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Longaeva Partners's TARA Position: Q1 2026 in Review

Longaeva Partners sold out of Protara Therapeutics (TARA) in Q1 2026, closing a stake of 33,857 shares — an estimated $180K sold.

Longaeva Partners first reported a position in TARA in Q4 2025 and held it in 1 quarter. The position peaked at $180K in Q4 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Longaeva Partners reported no remaining Protara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Longaeva Partners sold 33,857 Protara Therapeutics shares in Q1 2026, an estimated $180K.
  • Longaeva Partners first reported a position in Protara Therapeutics in Q4 2025 and held it in 1 quarter.
  • Longaeva Partners's Protara Therapeutics position peaked at $180K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Longaeva Partners's 13F filing for Q1 2026, filed 15 May 2026.